Skip to main content

Study of FF-10101-01 in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Trial Status: Active

A Phase 1 / 2a dose escalation and dose ranging study of FF-10101-01 in subjects with relapsed or refractory acute myeloid leukemia to determine the safety, tolerability, PK and preliminary efficacy. A total of 9 cohorts will be enrolled in Phase 1 to establish the Maximum Tolerated Dose (MTD). Phase 2a will consist of up to 3 dose levels (high, medium, and low) of which subjects with FLT3 mutations will randomly be assigned.

Inclusion Criteria

  • Subjects who are able and willing to give written informed consent - Documented primary or secondary AML, as defined by the WHO criteria (2008), by histopathology refractory to previous induction chemotherapy and/or relapsed after achieving remission with a prior chemotherapy and who are not candidates for other available therapy likely to confer clinical benefit. - For Phase 2a only: in addition to inclusion criteria 2 above, patients must have a FLT3 mutation of any type - Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 - In the absence of rapidly progressing disease, the interval from prior treatment to time of FF-10101-01 administration should be at least 14 days for cytotoxic agents other than hydroxyurea, at least 5 half-lives for non-cytotoxic agents, and 14 days for monoclonal antibody therapies. Hydroxyurea may be continued for a maximum of 14 days from the start of FF-10101-01 dosing, through Cycle 1 Day 14, with a maximal dose of 5 grams/day - Persistent chronic clinically significant toxicities from prior chemotherapy or surgery must be ≤Grade 2 - If subject has had a hematopoietic stem cell transplant, subject must be ≥60 days post-transplant with no clinically significant GVHD requiring systemic therapy - Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) ≤3 times the upper limit of normal and total bilirubin of ≤1.5x the upper limit of normal. If total bilirubin is equal to or exceeds 1.5x the upper limit of normal, the subject can still be included if direct bilirubin is ≤1.5x the upper limit of normal - Calculated creatinine clearance of ≥60 mL/min - Female subjects of childbearing potential and sexually mature male subjects must agree to use a medically accepted method of contraception other than an oral contraceptive for the duration of the study. Exclusion Criteria: - Subjects diagnosed with acute promyelocytic leukemia - Subjects with Bcr-Abl positive leukemia (chronic myelogenous leukemia in blast crisis) - Subjects with clinically active CNS leukemia - Subjects with major surgery within 28 days prior to the first administration of FF-10101-01 - Subjects with radiation therapy within 28 days prior to the first administration of FF-10101-01 - Subjects with active malignant disease requiring therapy other than AML or myelodysplastic syndrome with transformation into AML - Subjects with an active uncontrolled infection - Subjects with a medical condition, serious intercurrent illness, or other circumstance that, in the Investigator's judgment, could jeopardize the subject's safety as a study subject, or that could interfere with the study objectives - Subjects known to have human immunodeficiency virus infection, or who have active hepatitis B or C infection as determined by serological testing - Subjects with congestive heart failure, New York Heart Association (NYHA) Class 3 or 4, or subjects with a past history of congestive heart failure NYHA Class 3 or 4 and in whom echocardiogram or multiple gate acquisition (MUGA) scan performed within 3 months prior to screening or at screening showed a LVEF <40% - Female subjects who are pregnant or breast feeding - Subjects on 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) or other drugs known to have muscle toxicity - Subjects taking strong inhibitors of CYP3A4 will be excluded from the study unless therapeutic substitution is possible - Subjects taking strong inducers of CYP3A4 will be excluded from the study unless therapeutic substitution is possible - Use of systemic immunosuppressive agents within 14 days prior to first dose of FF-10101 - Subjects taking drugs known to cause Torsades de Pointes will be excluded from the study unless therapeutic substitution is possible - Subjects known to have long QT syndrome - Subjects with mean QTcF values following 3 ECGs conducted 5 minutes apart of >470 msec


Los Angeles
UCLA / Jonsson Comprehensive Cancer Center
Contact: Vladimir Kustanovich
Phone: 310-206-5756
San Francisco
UCSF Medical Center-Mount Zion


Northwestern University
Status: ACTIVE


Johns Hopkins University / Sidney Kimmel Cancer Center
Status: ACTIVE


Massachusetts General Hospital Cancer Center
Status: ACTIVE

New York

Roswell Park Cancer Institute
Status: ACTIVE


University of Pennsylvania / Abramson Cancer Center
Status: ACTIVE

Subjects will receive FF-10101-01 orally once a day repeated every 28 days =1 cycle Frequent blood draws will be collected to measure pharmacodynamic parameters and pharmacodynamic activity. Disease assessments, including bone marrow aspirates, will be performed at the beginning of cycles 1-3, and every 3 months thereafter. Subjects who demonstrate objective response or stable disease will be allowed to continue therapy with FF-10101-01 until , observation of unacceptable adverse events, or until the subject is no longer deriving benefit based on the opinion of the investigator. For Phase 2a long term phone follow-up for assessment of overall survival will also occur.

Trial Phase Phase I/II

Trial Type Treatment

Lead Organization
Fujifilm Pharmaceuticals U.S.A., Inc.

  • Primary ID FF-10101-US101/201
  • Secondary IDs NCI-2017-01566
  • ID NCT03194685